- Home
- SEVN vs BIOA Comparison
SEVN vs BIOA Comparison
Compare SEVN & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- BIOA
- Stock Information
- Founded
- SEVN 1986
- BIOA 2015
- Country
- SEVN United States
- BIOA United States
- Employees
- SEVN N/A
- BIOA N/A
- Industry
- SEVN Real Estate Investment Trusts
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- SEVN Real Estate
- BIOA Health Care
- Exchange
- SEVN Nasdaq
- BIOA Nasdaq
- Market Cap
- SEVN 173.7M
- BIOA 139.8M
- IPO Year
- SEVN N/A
- BIOA 2024
- Fundamental
- Price
- SEVN $11.86
- BIOA $3.99
- Analyst Decision
- SEVN Strong Buy
- BIOA Hold
- Analyst Count
- SEVN 4
- BIOA 4
- Target Price
- SEVN $14.50
- BIOA $5.67
- AVG Volume (30 Days)
- SEVN 36.2K
- BIOA 208.2K
- Earning Date
- SEVN 07-28-2025
- BIOA 05-06-2025
- Dividend Yield
- SEVN 11.90%
- BIOA N/A
- EPS Growth
- SEVN N/A
- BIOA N/A
- EPS
- SEVN 1.15
- BIOA N/A
- Revenue
- SEVN $30,074,000.00
- BIOA $1,451,000.00
- Revenue This Year
- SEVN $14.81
- BIOA N/A
- Revenue Next Year
- SEVN $2.73
- BIOA N/A
- P/E Ratio
- SEVN $10.23
- BIOA N/A
- Revenue Growth
- SEVN N/A
- BIOA N/A
- 52 Week Low
- SEVN $10.18
- BIOA $2.88
- 52 Week High
- SEVN $14.66
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- SEVN 51.68
- BIOA N/A
- Support Level
- SEVN $11.40
- BIOA N/A
- Resistance Level
- SEVN $11.99
- BIOA N/A
- Average True Range (ATR)
- SEVN 0.39
- BIOA 0.00
- MACD
- SEVN 0.00
- BIOA 0.00
- Stochastic Oscillator
- SEVN 49.46
- BIOA 0.00
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.